

GLAXOSMITHKLINE PLC
Form 6-K
April 13, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 13 April 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs V A Whyte
 - b) Position/status Company Secretary
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Acquisition of Ordinary Shares following the
 - b) Nature of the transaction re-investment of dividends paid to shareholders on 12 April 2018.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£14.3940	138
n/a (single transaction)	
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2018-04-12
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr I W Whyte
 - b) Position/status PCA of Mrs V A Whyte (Company Secretary)
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 12
 April 2018.

c) Price(s) and volume(s) Price(s) Volume(s)
 £14.3940 645
 n/a (single transaction)

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2018-04-12

f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs D Connor
 PCA of Mr R G Connor
 b) Position/status (President, Global
 Manufacturing & Supply)

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 12
 April 2018.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£14.3940	342
	n/a (single transaction)	
d) Aggregated information		
Aggregated volume Price		
e) Date of the transaction	2018-04-12	
f) Place of the transaction	London Stock Exchange (XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 13, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc